Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development
Reference number: GID-TA11489
Expected publication date: TBC
Following on from advice received from the company, timelines for this appraisal are to be confirmed whilst the company confirm their regulatory filing plans.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.